(Updated - July 18, 2025 2:19 PM EDT)

Baird analyst Brian Skorney downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades Hot Comments Hot Downgrades

TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)July 21, 2025 6:55 AM BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)July 21, 2025 6:03 AM ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPTJuly 18, 2025 2:11 PM FDA to Request Sarepta (SRPT) to Voluntarily Stop All Shipments of Elevidys - ReutersJuly 18, 2025 12:52 PM FDA Investigating Whether Sarepta's (SRPT) Elevidys Should Stay On The Market - BloombergJuly 18, 2025 12:09 PM Sarepta Therapeutics (SRPT) PT Lowered to $50 at BMO Capital Following Mangement CallJuly 18, 2025 12:04 PM SRPT Investors Have the Opportunity to Lead the Sarepta Securities Fraud Lawsuit with Faruqi & Faruqi, LLPJuly 18, 2025 11:46 AM Needham Downgrades Sarepta Therapeutics (SRPT) to HoldJuly 18, 2025 11:45 AM Sarepta Therapeutics (SRPT) CEO: did not disclose patient death on June 16 call as "It was neither material nor central to the topics at hand" - Conference CallJuly 18, 2025 10:43 AM Sarepta Therapeutics (SRPT) PT Lowered to $20 at BofA Securities, 'Safety reports could limit uptake of SRPT’s gene therapies'July 18, 2025 9:42 AM Morgan Stanley Reiterates Equalweight Rating on Sarepta Therapeutics (SRPT)July 18, 2025 9:33 AM Goldman Sachs Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)July 18, 2025 8:59 AM William Blair on Sarepta Therapeutics (SRPT): 'we continue to view the stock’s near-term upside potential as limited'July 18, 2025 8:58 AM Leerink Partners Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)July 18, 2025 8:55 AM Sarepta Therapeutics (SRPT) PT Lowered to $41 at OppenheimerJuly 18, 2025 8:34 AM Sarepta shares tumble after report of patient death in early-stage trialJuly 18, 2025 6:54 AM Sarepta Therapeutics (SRPT) PT Raised to $28 at TD CowenJuly 18, 2025 5:44 AM SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 17, 2025 4:02 PM Sarepta Therapeutics (SRPT) PT Lowered to $23 at RBC CapitalJuly 17, 2025 10:28 AM Sarepta Therapeutics (SRPT) PT Lowered to $32 at Piper SandlerJuly 17, 2025 10:24 AM Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)July 17, 2025 8:33 AM Needham Reiterates Buy Rating on Sarepta Therapeutics (SRPT)July 17, 2025 7:11 AM Sarepta Therapeutics (SRPT) PT Raised to $35 at BairdJuly 17, 2025 7:09 AM Sarepta Therapeutics (SRPT) PT Lowered to $65 at Wells FargoJuly 17, 2025 7:07 AM H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)July 17, 2025 6:48 AM Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)July 17, 2025 6:42 AM Sarepta Therapeutics (SRPT) PT Raised to $32 at BarclaysJuly 17, 2025 4:29 AM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPTJuly 16, 2025 4:58 PM After-hours movers: United Airlines, Sarepta Therapeutic, MP MaterialsJuly 16, 2025 4:54 PM Form 8-K Sarepta Therapeutics, For: Jul 14July 16, 2025 4:11 PM Sarepta cuts 36% of workforce, expects $400M in annual savingsJuly 16, 2025 4:01 PM Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS LabelJuly 16, 2025 4:01 PM